Nevro1™ Proven to Immediately Transfix Sacroiliac (SI) Joint to Allow for Long-term SI Joint Fusion REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NVRO), a global medical device ...
Senza® HFX iQ™ is the First and Only SCS System that Uses Artificial Intelligence to Optimize and Maintain Pain Relief Using Each Patient's Response REDWOOD CITY, Calif., March 7, 2023 /PRNewswire/ -- ...
Furthering Nevro's (NVRO) body of evidence as an innovation leader in pain management, data highlights the company's posterior integrated transfixation cage system REDWOOD CITY, Calif., Nov. 18, 2024 ...
REDWOOD CITY, Calif., May 14, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, ...
Evidence Published in Diabetes Research and Clinical Practice Shows 10 kHz Therapy Yields Lasting Pain Relief and Enhances Health-Related Quality of Life and Sleep REDWOOD CITY, Calif., Aug. 16, 2023 ...
Nevro, a chronic pain medical device company, today announced the acquisition of Vyrsa Technology, a company focused on minimally invasive treatments for patients with chronic sacroiliac joint (SI ...
Nevro Corp. NVRO is well-poised for growth in the coming quarters, courtesy of its research and development (R&D) edge. The optimism, led by a solid first-quarter 2024 performance and continued ...
REDWOOD CITY, Calif., Feb. 28, 2024 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results